Australia's Telix Pharmaceuticals scales record peak on upbeat revenue forecast

Feb 21 (Reuters) - Shares of Telix Pharmaceuticals TLX.AX surged to a record high on Friday after the company forecast annual bumper revenue, while its full-year earnings for 2024 soared more than ninefold.

The Australian biopharmaceutical firm's stock jumped as much as 15.3% by 0223 GMT, making it one of the top gainers in the benchmark S&P/ASX 200 .AXJO index, which was down 0.2%.

Telix forecast on Thursday full-year 2025 revenue to be in the range of A$1.18 billion to A$1.23 billion ($755.55 million to $787.57 million), above consensus estimate of A$1.03 billion, according to analysts at TD Cowen.

($1 = 1.5618 Australian dollars)